海思科创新药HSK39297片上市许可获受理

Core Viewpoint - The company, Haikang (002653), announced that its subsidiary Sichuan Haikang Pharmaceutical Co., Ltd. received a notice from the National Medical Products Administration regarding the acceptance of the registration application for the drug HSK39297, aimed at treating adult patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) who have not previously received complement inhibitors [1] Group 1 - The drug HSK39297 is classified as a Class 1 chemical drug according to China's new chemical drug registration classification regulations [1] - HSK39297 is the first-tier CFB inhibitor targeting PNH in China, addressing a significant unmet clinical need [1] - The market outlook for HSK39297 is positive due to the high demand for treatment options in this therapeutic area [1]